AGENDA
 .
12:30  1:30 Registration & Networking
1:30  1:40 Welcome and Opening Remarks
Phil Greenberg, Head of the Program in Immunology and member of the Clinical Research Division, Fred Hutch; Professor of Medicine/Oncology and of Immunology, University of Washington
Jim Edwards, Publisher, Xconomy
1:40  2:10 Can CAR-T Be Tamed?
Hans Bishop, CEO, Juno Therapeutics
Richard Maziarz, Medical Director, Adult Blood and Marrow Stem Cell Transplant Program, Oregon Health and Science University
Alex Lash, National Biotechnology Editor, Xconomy (moderator)
2:10  2:40 Chasing Cancer Vaccines
Andrew Allen, CEO, Gritstone Oncology
Jay Venkatesan, President, Alpine Immune Sciences
Alex Lash, National Biotechnology Editor, Xconomy (moderator)
2:40  3:10 Teaming Up On Immunotherapy’s Frontier
Jill O’Donnell-Tormey, CEO, Cancer Research Institute
Ilya Shmulevich, Professor, Institute for Systems Biology
Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Company
Andrew Albertson, Partner, Fenwick & West (moderator)
3:10  3:40 Networking Break
3:40 4:05 Kids, Cancer Care, and Lessons Learned
Michael Jensen, MD, Director, Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute
4:05 – 4:35 Deciphering The Immune System
Brad Gray, CEO, NanoString Technologies
Chad Robins, President & CEO, Adaptive Biotechnologies
Alex Lash, National Biotechnology Editor, Xconomy (moderator)
4:35 – 5:05 T Cell Treatments Under The Radar
Maria Fardis, CEO, Lion Biotechnologies
Sylvia Lee, Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
5:05 – 5:30 How Lung Cancer Became Immunotherapy’s Biggest Success
Renato Martins
, Medical Director, Thoracic/Head and Neck Oncology, University of Washington School of Medicine
5:30 – 6:30 Networking Reception

 

*Schedule is subject to change.

Register here.